AC T06144
XX
ID T06144
XX
DT 13.09.2004 (created); oke.
DT 30.07.2014 (updated); sla.
CO Copyright (C), QIAGEN.
XX
FA p73epsilon
XX
SY tumor protein p73 isoform k; tumor suppressor p73, isoform epsilon.
XX
OS human, Homo sapiens
OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates
XX
GE G005523 TP73; HGNC: tp73.
XX
CL C0057; P53; 6.3.1.0.3.5.
XX
SZ 555 AA; 61.7 kDa (calc.).
XX
SQ MAQSTATSPDGGTTFEHLWSSLEPDSTYFDLPQSSRGNNEVVGGTDSSMDVFHLEGMTTS
SQ VMAQFNLLSSTMDQMSSRAASASPYTPEHAASVPTHSPYAQPSSTFDTMSPAPVIPSNTD
SQ YPGPHHFEVTFQQSSTAKSATWTYSPLLKKLYCQIAKTCPIQIKVSTPPPPGTAIRAMPV
SQ YKKAEHVTDVVKRCPNHELGRDFNEGQSAPASHLIRVEGNNLSQYVDDPVTGRQSVVVPY
SQ EPPQVGTEFTTILYNFMCNSSCVGGMNRRPILIIITLEMRDGQVLGRRSFEGRICACPGR
SQ DRKADEDHYREQQALNESSAKNGAASKRAFKQSPPAVPALGAGVKKRRHGDEDTYYLQVR
SQ GRENFEILMKLKESLELMELVPQPLVDSYRQQQQLLQRPPRDAQQPWPRSASQQRRDEQQ
SQ PQRPVHGLGVPLHSATPLPRRPQPRDLGALKIPEQYRMTIWRGLQDLKQGHDYSTAQQLL
SQ RSSNAATISIGGSGELQRQRVMEAVHFRVRHTITIPNRGGPGGGPDEWADFGFDLPDCKA
SQ RKQPIKEEFTEAEIH
XX
SC Swiss-Prot#O15350-5
XX
FT 102 391 
PF00478; IMP dehydrogenase / GMP reductase domain.
FT 113 309 
PF00870; P53 DNA-binding domain.
FT 316 555 
suppresses transcriptional activity of p73beta [3].
FT 345 386 
PF07710; P53 tetramerisation motif.
FT 400 445 
different from p73alpha [3].
XX
SF several alternative products are known, p73alpha T04931, p73beta T06137, p73gamma T06142, p73delta T06143, p73epsilon T06144, p73zeta T06145, p73kappa T06139, p73eta T06179, DeltaN p73alpha T06002, DeltaN p73beta T06003, DeltaNp73gamma T06013;
SF C-terminal structure is very similar to that of p73alpha, and suppresses transcriptional activity of p73beta [3];
XX
CP leukemic cells [2].
CN completely absent in mature myeloid cells [2].
XX
FF is able to weakly activate transcription via p53 consensus sequence [3] [4];
FF suppresses transcriptional activity of p53 [4];
XX
MX M00761 V$P53DECAMER_Q2.
MX M03558 V$P73_Q6.
XX
DR TRANSPATH: MO000043753.
DR UniProtKB: O15350-5;
XX
RN [1]; RE0024717.
RX PUBMED: 10381648.
RA De Laurenzi V. D., Catani M. V., Terrinoni A., Corazzari M., Melino G., Costanzo A., Levrero M., Knight R. A.
RT Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta.
RL Cell Death Differ. 6:389-390 (1999).
RN [2]; RE0024731.
RX PUBMED: 11027640.
RA Tschan M. P., Grob T. J., Peters U. R., Laurenzi V. D., Huegli B., Kreuzer K. A., Schmidt C. A., Melino G., Fey M. F., Tobler A., Cajot J. F.
RT Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia.
RL Biochem. Biophys. Res. Commun. 277:62-65 (2000).
RN [3]; RE0024768.
RX PUBMED: 11389695.
RA Ueda Y., Hijikata M., Takagi S., Chiba T., Shimotohno K.
RT Transcriptional activities of p73 splicing variants are regulated by inter-variant association.
RL Biochem. J. 356:859-866 (2001).
RN [4]; RE0024769.
RX PUBMED: 10490834.
RA Ueda Y., Hijikata M., Takagi S., Chiba T., Shimotohno K.
RT New p73 variants with altered C-terminal structures have varied transcriptional activities.
RL Oncogene 18:4993-4998 (1999).
XX
//